At the heart of COVID-19.
Identifieur interne : 000311 ( Main/Corpus ); précédent : 000310; suivant : 000312At the heart of COVID-19.
Auteurs : Inayat Hussain Khan ; Syeda Anum Zahra ; Sevim Zaim ; Amer HarkySource :
- Journal of cardiac surgery [ 1540-8191 ] ; 2020.
English descriptors
- KwdEn :
- Cardiovascular Diseases (diagnosis), Cardiovascular Diseases (epidemiology), China (epidemiology), Comorbidity (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (epidemiology), Female (MeSH), Global Health (MeSH), Humans (MeSH), Male (MeSH), Pandemics (prevention & control), Pandemics (statistics & numerical data), Pneumonia, Viral (diagnosis), Pneumonia, Viral (epidemiology), Risk Assessment (MeSH), Survival Analysis (MeSH).
- MESH :
- geographic , epidemiology : China.
- diagnosis : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Pandemics.
- statistics & numerical data : Pandemics.
- Comorbidity, Female, Global Health, Humans, Male, Risk Assessment, Survival Analysis.
Abstract
Coronavirus disease (COVID-19) first presented in Wuhan, Hubei province, China in December 2019. Since then, it has rapidly spread across the world, and is now formally considered a pandemic. The disease does not discriminate but increasing age and the presence of comorbidities are associated with severe form of the disease and poor outcomes. Although the prevalence of COVID-19 in patients with cardiovascular disease is under-reported, there is evidence that pre-existing cardiac disease can render individuals vulnerable. It is thought that COVID-19 may have both a direct and indirect effect on the cardiovascular system; however, the primary mechanism of underlying cardiovascular involvement is still uncertain. Of particular interest is the role of angiotensin-converting enzyme 2, which is well known for its cardiovascular effects and is also considered to be important in the pathogenesis of COVID-19. With a range of different drug candidates being suggested, effective anti-virals and vaccines are an area of on-going research. While our knowledge of COVID-19 continues to rapidly expand, this review highlights recent advances in our understanding of the interaction between COVID-19 and the cardiovascular system.
DOI: 10.1111/jocs.14596
PubMed: 32369872
Links to Exploration step
pubmed:32369872Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">At the heart of COVID-19.</title><author><name sortKey="Khan, Inayat Hussain" sort="Khan, Inayat Hussain" uniqKey="Khan I" first="Inayat Hussain" last="Khan">Inayat Hussain Khan</name><affiliation><nlm:affiliation>Department of Medicine, St George's Hospital Medical School, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Zahra, Syeda Anum" sort="Zahra, Syeda Anum" uniqKey="Zahra S" first="Syeda Anum" last="Zahra">Syeda Anum Zahra</name><affiliation><nlm:affiliation>Department of Medicine, St George's Hospital Medical School, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Zaim, Sevim" sort="Zaim, Sevim" uniqKey="Zaim S" first="Sevim" last="Zaim">Sevim Zaim</name><affiliation><nlm:affiliation>Department of Medicine, University of Liverpool School of Medicine, Liverpool, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Harky, Amer" sort="Harky, Amer" uniqKey="Harky A" first="Amer" last="Harky">Amer Harky</name><affiliation><nlm:affiliation>Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32369872</idno><idno type="pmid">32369872</idno><idno type="doi">10.1111/jocs.14596</idno><idno type="wicri:Area/Main/Corpus">000311</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000311</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">At the heart of COVID-19.</title><author><name sortKey="Khan, Inayat Hussain" sort="Khan, Inayat Hussain" uniqKey="Khan I" first="Inayat Hussain" last="Khan">Inayat Hussain Khan</name><affiliation><nlm:affiliation>Department of Medicine, St George's Hospital Medical School, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Zahra, Syeda Anum" sort="Zahra, Syeda Anum" uniqKey="Zahra S" first="Syeda Anum" last="Zahra">Syeda Anum Zahra</name><affiliation><nlm:affiliation>Department of Medicine, St George's Hospital Medical School, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Zaim, Sevim" sort="Zaim, Sevim" uniqKey="Zaim S" first="Sevim" last="Zaim">Sevim Zaim</name><affiliation><nlm:affiliation>Department of Medicine, University of Liverpool School of Medicine, Liverpool, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Harky, Amer" sort="Harky, Amer" uniqKey="Harky A" first="Amer" last="Harky">Amer Harky</name><affiliation><nlm:affiliation>Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of cardiac surgery</title><idno type="eISSN">1540-8191</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cardiovascular Diseases (diagnosis)</term><term>Cardiovascular Diseases (epidemiology)</term><term>China (epidemiology)</term><term>Comorbidity (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (epidemiology)</term><term>Female (MeSH)</term><term>Global Health (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Pandemics (prevention & control)</term><term>Pandemics (statistics & numerical data)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (epidemiology)</term><term>Risk Assessment (MeSH)</term><term>Survival Analysis (MeSH)</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Comorbidity</term><term>Female</term><term>Global Health</term><term>Humans</term><term>Male</term><term>Risk Assessment</term><term>Survival Analysis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease (COVID-19) first presented in Wuhan, Hubei province, China in December 2019. Since then, it has rapidly spread across the world, and is now formally considered a pandemic. The disease does not discriminate but increasing age and the presence of comorbidities are associated with severe form of the disease and poor outcomes. Although the prevalence of COVID-19 in patients with cardiovascular disease is under-reported, there is evidence that pre-existing cardiac disease can render individuals vulnerable. It is thought that COVID-19 may have both a direct and indirect effect on the cardiovascular system; however, the primary mechanism of underlying cardiovascular involvement is still uncertain. Of particular interest is the role of angiotensin-converting enzyme 2, which is well known for its cardiovascular effects and is also considered to be important in the pathogenesis of COVID-19. With a range of different drug candidates being suggested, effective anti-virals and vaccines are an area of on-going research. While our knowledge of COVID-19 continues to rapidly expand, this review highlights recent advances in our understanding of the interaction between COVID-19 and the cardiovascular system.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32369872</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8191</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of cardiac surgery</Title><ISOAbbreviation>J Card Surg</ISOAbbreviation></Journal><ArticleTitle>At the heart of COVID-19.</ArticleTitle><Pagination><MedlinePgn>1287-1294</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jocs.14596</ELocationID><Abstract><AbstractText>Coronavirus disease (COVID-19) first presented in Wuhan, Hubei province, China in December 2019. Since then, it has rapidly spread across the world, and is now formally considered a pandemic. The disease does not discriminate but increasing age and the presence of comorbidities are associated with severe form of the disease and poor outcomes. Although the prevalence of COVID-19 in patients with cardiovascular disease is under-reported, there is evidence that pre-existing cardiac disease can render individuals vulnerable. It is thought that COVID-19 may have both a direct and indirect effect on the cardiovascular system; however, the primary mechanism of underlying cardiovascular involvement is still uncertain. Of particular interest is the role of angiotensin-converting enzyme 2, which is well known for its cardiovascular effects and is also considered to be important in the pathogenesis of COVID-19. With a range of different drug candidates being suggested, effective anti-virals and vaccines are an area of on-going research. While our knowledge of COVID-19 continues to rapidly expand, this review highlights recent advances in our understanding of the interaction between COVID-19 and the cardiovascular system.</AbstractText><CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Inayat Hussain</ForeName><Initials>IH</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-9209-1664</Identifier><AffiliationInfo><Affiliation>Department of Medicine, St George's Hospital Medical School, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahra</LastName><ForeName>Syeda Anum</ForeName><Initials>SA</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-0253-7330</Identifier><AffiliationInfo><Affiliation>Department of Medicine, St George's Hospital Medical School, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaim</LastName><ForeName>Sevim</ForeName><Initials>S</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1861-0531</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Liverpool School of Medicine, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harky</LastName><ForeName>Amer</ForeName><Initials>A</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-5507-5841</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Surg</MedlineTA><NlmUniqueID>8908809</NlmUniqueID><ISSNLinking>0886-0440</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cardiovascular</Keyword><Keyword MajorTopicYN="N">heart</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32369872</ArticleId><ArticleId IdType="doi">10.1111/jocs.14596</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Ren L, Wang Y, Wu Z, et al. Identification of a novel coronavirus causing severe pneumonia in human. Chin Med J. 2020:1.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.</Citation></Reference><Reference><Citation>World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed 12 April 2020.</Citation></Reference><Reference><Citation>Flahault A. Has China faced only a herald wave of SARS-CoV-2? The Lancet. 2020;395(10228):947.</Citation></Reference><Reference><Citation>Grech V. Unknown unknowns-COVID-19 and potential global mortality. Early Hum Dev. 2020;144:105026.</Citation></Reference><Reference><Citation>Bialek S, Boundy E, Bowen V, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346.</Citation></Reference><Reference><Citation>Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020:2000547.</Citation></Reference><Reference><Citation>Zheng Y, Ma Y, Zhang J, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020.</Citation></Reference><Reference><Citation>Madjid M, Safavi-Naeini P, Solomon S, et al. Potential effects of coronaviruses on the cardiovascular system. JAMA Cardiol. 2020.</Citation></Reference><Reference><Citation>Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-423.</Citation></Reference><Reference><Citation>Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long Structural studies of SARS coronavirus. J Virol. 2020;94:7.</Citation></Reference><Reference><Citation>Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Med. 2005;11(8):875-879.</Citation></Reference><Reference><Citation>Kolifarhood G, Aghaali M, Saadati H, et al. Epidemiological and clinical aspects of COVID-19; a narrative review. Journals.sbmu.ac.ir. 2020. [Internet]. http://journals.sbmu.ac.ir/AAEM/index.php/AAEM/article/view/620. Accessed 11 April 2020.</Citation></Reference><Reference><Citation>Guan W, Ni H, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020.</Citation></Reference><Reference><Citation>World Health Organisation. Pneumonia of unknown cause-China. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/. Accessed 11 April 2020.</Citation></Reference><Reference><Citation>World Health Organisation. Coronavirus disease 2019 (COVID-19) situation report-83 [Internet]. 2020. https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125. Accessed 12 April 2020.</Citation></Reference><Reference><Citation>Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020.</Citation></Reference><Reference><Citation>Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323(13):1239.</Citation></Reference><Reference><Citation>Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. JACC. 2020.</Citation></Reference><Reference><Citation>Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020.</Citation></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.</Citation></Reference><Reference><Citation>Bonow RO, Fonarow GC, O'Gara PT, et al. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020.</Citation></Reference><Reference><Citation>Wu C, Postema P, Arbelo E, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm. 2020.</Citation></Reference><Reference><Citation>Hu H, Ma F, Wei X, et al. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020.</Citation></Reference><Reference><Citation>Zeng JH, Liu Y-X, Yuan J, et al. First case of COVID-19 infection with fulminant myocarditis complication: case report and insights. Infection. 2020.</Citation></Reference><Reference><Citation>Chapman A, Adamson P, Mills N. Assessment and classification of patients with myocardial injury and infarction in clinical practice. Heart. 2016;103(1):10-18.</Citation></Reference><Reference><Citation>Oudit G, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618-625.</Citation></Reference><Reference><Citation>Seguin A, Galicier L, Boutboul D, et al. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest. 2016;149(5):1294-1301.</Citation></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020.</Citation></Reference><Reference><Citation>Rivara M, Bajwa E, Januzzi J, et al. Prognostic significance of elevated cardiac troponin-T levels in acute respiratory distress syndrome patients. PLoS One. 2012;7(7):e40515.</Citation></Reference><Reference><Citation>Court O, Kumar A, Parrillo J, et al. Clinical review: myocardial depression in sepsis and septic shock. Crit Care. 2002;6(6):500.</Citation></Reference><Reference><Citation>Kochi A, Tagliari A, Forleo G, et al. Cardiac and arrhythmic complications in Covid-19 patients. J Cardiovasc Electrophysiol. 2020.</Citation></Reference><Reference><Citation>Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020.</Citation></Reference><Reference><Citation>Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the padua prediction score. J Thromb Haemost. 2010;8(11):2450-2457.</Citation></Reference><Reference><Citation>Xu J, Wang L, Zhao L, et al. Risk assessment of venous thromboembolism and bleeding in COVID-19 patients. Pulmonology. 2020.</Citation></Reference><Reference><Citation>Du R, Liang L, Yang C, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020:2000524</Citation></Reference><Reference><Citation>Fried J, Ramasubbu K, Bhatt R, et al. The variety of cardiovascular presentations of COVID-19. Circulation. 2020.</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-1062.</Citation></Reference><Reference><Citation>Beeching NFT, Fowler R. Coronavirus disease 2019 (COVID-19): BMJ best practice; 2020. https://bestpractice.bmj.com/topics/en-gb/3000168. Accessed 11 April 2020.</Citation></Reference><Reference><Citation>Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and Multi-Organ Response, Current Problems in Cardiology, 2020, https://doi.org/10.1016/j.cpcardiol.2020.100618</Citation></Reference><Reference><Citation>World Health Organisation. “Solidarity” clinical trial for COVID-19 treatments 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. Accessed 11 April 2020.</Citation></Reference><Reference><Citation>Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci. 2020:202004168</Citation></Reference><Reference><Citation>Khashkhusha TR, Chan JSK, Harky A. ACE inhibitors and COVID-19: we don't know yet. J Card Surg. 2020. https://doi.org/10.1111/jocs.14582</Citation></Reference><Reference><Citation>European Society of Cardiology. Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers [Internet]. Escardio.org. 2020. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed 12 April 2020.</Citation></Reference><Reference><Citation>Tam C, Cheung K, Lam S, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020.</Citation></Reference><Reference><Citation>Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017;7:1.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000311 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000311 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32369872
|texte= At the heart of COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32369872" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |